Rituximab is an anti-CD20 monoclonal antibody that has transformed outcomes in B-cell malignancies. It is used as part of R-CHOP in DLBCL, R-CVP or R-Bendamustine in follicular lymphoma, and FCR in CLL. At our centre, Rituximab infusions are administered with careful pre-medication (antihistamine, paracetamol, corticosteroid) to minimise infusion reactions, and patients are closely monitored throughout. Rituximab is also used in maintenance therapy after induction to prolong remission. Patients receiving Rituximab are counselled about the risk of infection (particularly reactivation of Hepatitis B) and are screened and managed appropriately before commencement.
📋 Treatment Overview
Type
Rituximab Infusion Therapy
Speciality
Oncology & Haematology
Administered By
Dr. Ravindra Joshi
📅 Schedule a Consultation
Talk to Dr. Joshi about whether this treatment is right for you. OPD: Mon–Thu, 10 AM – 1 PM.